VTT Technical Research Centre of Finland Licenses MetaCore from GeneGo
News Jun 25, 2008
GeneGo, Inc. has announced that VTT has licensed MetaCore™. VTT develops high-throughput methods for cancer research, drug discovery and diagnostics. The focus is in investigating mechanisms of cancer development and progression, identification of therapeutic targets and exploration of the mechanism of action of anti-cancer compounds.
VTT will utilize MetaCore and MetaDrug in high-throughput compound screening, RNA interference experiments, cell biology and bioinformatics projects to identify pathways and networks important in translational cancer research.
There are 85 researchers and staff members working in VTT's Medical Biotechnology Knowledge Centre in Turku. The research is funded by the European Commission and the Academy of Finland.
VTT accommodates two EU Marie Curie Centre of Excellence teams and coordinates the Academy of Finland Centre of Excellence for translational genome-wide biology
Global Experts Meeting on Frontiers in Biosimilars and Biologics Congress
Oct 24 - Oct 26, 2019